Trebananib

DB12056InvestigationalProtein Based Therapies

Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon...

Mechanism: Pharmacologically active on Angiopoietin-2 and Angiopoietin-1
Curator reviewed
Code names: AMG386

Resolves to

Compound

UNIIX8Y5U6NC7ECAS894356-79-7

Targets

O15123ANGPT2Q15389ANGPT1P32245MC4RP23510TNFSF4P36544CHRNA7Q96BI3APH1AQ8WW43APH1BQ9NZ42PSENEN+2 more

What you can answer from here — as of June 15, 2026

10Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

48Drug interactionsStructured to mechanism, not free text

30Clinical trialsPhase, status and sponsor resolved per trial

14+ReferencesStructured and connected to the statements they support

Which drugs share a target with Trebananib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account